Insulin - PowderJect Pharmaceuticals

Drug Profile

Insulin - PowderJect Pharmaceuticals

Latest Information Update: 10 Sep 2002

Price : $50

At a glance

  • Originator PowderJect Pharmaceuticals
  • Developer AlgoRx Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 09 Aug 2002 Discontinued - Preclinical for Diabetes mellitus in United Kingdom (Transdermal)
  • 29 Mar 2002 PowderJect Pharmaceuticals has sold its non-vaccine business to AlgoRx
  • 17 Jan 2002 PowderJect Pharmaceuticals intends to license out the drug applications of its powder injection technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top